Stock Chart

LIMN

$3.90 +4.00%
Score: 32.7 AVOID NEW MONEY
Pro
Screener
Vol: 1.00x (vs SPY: 1.0x | vs QQQ: 1.0x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
No qualifying chart pattern in the trailing 60 sessions — we only flag setups that pass our quality gate.
Technical Chart
OVERLAYS
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER
SETTINGS
Active (2)
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About LIMN - Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.

Key Statistics

Market Cap $5M

More LIMN Analysis

Buy or Sell Analysis Price Prediction AI Analysis Fair Price Options Advisor Trendline Analysis

This LIMN stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track LIMN's price movements with trendlines, gamma walls, and key support/resistance levels.